CCL5 and Alzheimer disease: Results showed a decrease in the expression of CCL5 in PBMCs in the BBB models by 17.48-fold for control patients, 14-90-fold for mild AD patients and 28.73-fold for moderate AD patients versus PBMCs cultured alone (Table 1).